Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at firstname.lastname@example.org.
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
"We're building on three successful phase IIs... they've had one phase II programme that failed, and they have no other ones. What they're choosing to do is really…
"Two new reports by Evaluate Ltd’s news and analysis arm, EP Vantage, highlight the wider trend."
"EP Vantage - Newsletter provider, biotech, healthcare"
"I think [Roche's (OTCQX:RHHBY) emicizumab has been shown to be that," Guy Young of the Children's Hospital Los Angeles tells EP Vantage."
"When the recently listed UK biotech's chief executive spoke to EP Vantage two years ago the focus was cancer and Imbruvica-resistant patients"
"According to E.P. Vantage’s Jacob Plieth, the El Segundo facility would also service Europe."
As ICER noted in its May whitepaper, worldwide revenues from orphan drugs topped $100 billion in 2015, and could double over the next five years, according to…